AMRC's response to ABPI's application for a judicial review Published: 10 July 2017 Commenting on the ABPI’s application for a judicial review, Aisling Burnand chief executive of the Association of Medical Research Charities said: “The decision taken by NICE and NHS England earlier this year to impose a budget impact test amounts to rationing by delay. Patients in England already face delayed access to new treatments and medicines that are approved by NICE as being clinically and cost effective. “Whilst we accept that things need to change and that a new approach is needed, we express disappointment at the consultation process and the lack of engagement with key stakeholders in making and announcing the decision. “We call on all parties to come together a find a way forward for the sake of patients across the country. The Accelerated Access Review makes positive and helpful recommendations to accelerate the use of innovation in the NHS – we would ask that these are brought into a new approach and form part of the Life Sciences Industrial Strategy. “We will monitor the judicial review with close interest. Having further clarity, certainty and transparency will be important for patients who need to access to new treatments.” Manage Cookie Preferences
Commenting on the ABPI’s application for a judicial review, Aisling Burnand chief executive of the Association of Medical Research Charities said: “The decision taken by NICE and NHS England earlier this year to impose a budget impact test amounts to rationing by delay. Patients in England already face delayed access to new treatments and medicines that are approved by NICE as being clinically and cost effective. “Whilst we accept that things need to change and that a new approach is needed, we express disappointment at the consultation process and the lack of engagement with key stakeholders in making and announcing the decision. “We call on all parties to come together a find a way forward for the sake of patients across the country. The Accelerated Access Review makes positive and helpful recommendations to accelerate the use of innovation in the NHS – we would ask that these are brought into a new approach and form part of the Life Sciences Industrial Strategy. “We will monitor the judicial review with close interest. Having further clarity, certainty and transparency will be important for patients who need to access to new treatments.”